Maraviroc
Maraviroc structure
|
Common Name | Maraviroc | ||
|---|---|---|---|---|
| CAS Number | 376348-65-1 | Molecular Weight | 513.666 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C29H41F2N5O | Melting Point | 79-81ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
|
Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines.
Eur. J. Immunol. 45(1) , 101-12, (2015) Serum amyloid A (SAA) is an acute phase protein that is upregulated in inflammatory diseases and chemoattracts monocytes, lymphocytes, and granulocytes via its G protein-coupled receptor formyl peptide receptor like 1/formyl peptide receptor 2 (FPRL1/FPR2). H... |
|
|
Procoagulant and proinflammatory effects of red blood cells on lipopolysaccharide-stimulated monocytes.
J. Thromb. Haemost. 13 , 1676-82, (2015) We aimed to evaluate the mechanisms underlying the effects of red blood cells (RBCs) on the reactivity of monocytes to lipopolysaccharide (LPS) stimulation.Measurements of tissue factor (TF) antigen and activity were performed on freshly isolated white blood ... |
|
|
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Antimicrob. Agents Chemother. 59(1) , 397-406, (2014) GSK1265744 is a new HIV integrase strand transfer inhibitor (INSTI) engineered to deliver efficient antiviral activity with a once-daily, low-milligram dose that does not require a pharmacokinetic booster. The in vitro antiviral profile and mechanism of actio... |
|
|
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.
Lancet HIV 1 , e60-7, (2015) Immune reconstitution inflammatory syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in patients with HIV. IRIS is associated with an increased risk of admission to hospital and death. We assessed whether CCR5 blockade with maraviroc re... |
|
|
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).
J. Antimicrob. Chemother. 69(7) , 1903-10, (2014) Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the general population. The NAFLD spectrum ranges from simple steatosis to cirrhosis. The chemokine CCL5/RANTES plays an important role in the progression of hepati... |